Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4934)	7/19/2006 1:50:48 PM
From: Ian@SI	Read Replies (1) \| Respond to of 12215

Yes, regardless of how the Merck, JNJ, obesity and "improved plavix" projects go, arna will never again be able to access public markets. They are doomed. I trust this is your way of suggesting that I remove my head from somewhere so that I can better see the light! <vbg> They just seem to have an awful lot on the go and not much money to finance all of the activity. ... or is there a high probability that milestone payments will take care of that?

To: scaram(o)uche who wrote (4934)	7/19/2006 3:16:36 PM
From: dr.praveen	Read Replies (2) \| Respond to of 12215

Roche exercises its option on Ipsen's anti-diabetic medicine for type 2 diabetes Further to the agreement signed in October 2003, Roche announced today its decision to exercise its option to exclusively... Basel (Switzerland) and Paris (France), 19 July 2006 – Further to the agreement signed in October 2003, Roche announced today its decision to exercise its option to exclusively licence, develop and market Ipsen’s patented anti-diabetic drug BIM 51077. This GLP-1 medicine has shown a good efficacy signal and latest data from phase I + II clinical studies showed potential to be more conveniently administered than existing members of the class, which would facilitate patient compliance. Roche has been granted worldwide rights, except in Japan where these rights are shared with Teijin (Ipsen’s Japanese partner), and in France where Ipsen may elect to retain co-marketing rights.